Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Retained Earnings (2016 - 2026)

Anika Therapeutics has reported Retained Earnings over the past 17 years, most recently at $55.7 million for Q1 2026.

  • Quarterly Retained Earnings fell 16.56% to $55.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $55.7 million through Mar 2026, down 16.56% year-over-year, with the annual reading at $60.8 million for FY2025, 15.18% down from the prior year.
  • Retained Earnings was $55.7 million for Q1 2026 at Anika Therapeutics, down from $60.8 million in the prior quarter.
  • Over five years, Retained Earnings peaked at $222.6 million in Q1 2022 and troughed at -$6.6 million in Q3 2023.
  • The 5-year median for Retained Earnings is $66.8 million (2025), against an average of $88.9 million.
  • Year-over-year, Retained Earnings skyrocketed 4630.13% in 2022 and then tumbled 105.28% in 2025.
  • A 5-year view of Retained Earnings shows it stood at $210.7 million in 2022, then plummeted by 39.23% to $128.1 million in 2023, then plummeted by 44.03% to $71.7 million in 2024, then fell by 15.18% to $60.8 million in 2025, then dropped by 8.32% to $55.7 million in 2026.
  • Per Business Quant, the three most recent readings for ANIK's Retained Earnings are $55.7 million (Q1 2026), $60.8 million (Q4 2025), and -$4.9 million (Q3 2025).